A5053214126- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Glycosylation and Glycoproteins Research
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Cancer-related Molecular Pathways
- Galectins and Cancer Biology
- Insect Pest Control Strategies
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Agricultural pest management studies
- Cardiac and Coronary Surgery Techniques
- Telomeres, Telomerase, and Senescence
- Airway Management and Intubation Techniques
- Insect-Plant Interactions and Control
- Obstructive Sleep Apnea Research
- Yeasts and Rust Fungi Studies
- Neuroendocrine Tumor Research Advances
- NF-κB Signaling Pathways
- Parathyroid Disorders and Treatments
- Carbohydrate Chemistry and Synthesis
- MicroRNA in disease regulation
Bielefeld University
2024
Klinikum Ingolstadt
2020
Agroscope
2018
Universität Ulm
2008-2017
Swiss Federal Institute for Forest, Snow and Landscape Research
2016
University of Cologne
2010-2012
Heidelberg University
2005-2012
Schott (Germany)
2012
German Cancer Research Center
2005-2012
Bühler (United Kingdom)
2011
The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the mutations CLL.We assessed by denaturing high-performance liquid chromatography (exons 2 11) a randomized prospective trial (n = 375) with follow-up 52.8 months (German CLL Study Group CLL4 trial; fludarabine [F] v F + cyclophosphamide [FC]).We found 8.5% patients (28 328 patients). None showed complete response. In mutation,...
Purpose To determine the clinical significance of flow cytometric minimal residual disease (MRD) quantification in chronic lymphocytic leukemia (CLL) addition to pretherapeutic risk factors and compare prognostic impact MRD between arms German CLL Study Group CLL8 trial. Patients Methods levels were prospectively quantified 1,775 blood bone marrow samples from 493 patients randomly assigned receive fludarabine cyclophosphamide (FC) or FC plus rituximab (FCR). categorized by into low- (<...
We investigated the safety and efficacy of bendamustine rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL).In all, 117 patients, age 34 to 78 years, 46.2% at Binet stage C, 25.6% 70 years or older received BR chemoimmunotherapy for first-line treatment CLL. Bendamustine was administered a dose 90 mg/m(2) on days 1 2 combined 375 day 0 first course 500 during subsequent courses up six courses.Overall response rate 88.0% (95% CI, 80.7% 100.0%) complete...
The objective of this trial was to evaluate safety and efficacy bendamustine combined with rituximab (BR) in patients relapsed and/or refractory chronic lymphocytic leukemia (CLL).Seventy-eight patients, including 22 fludarabine-refractory disease (28.2%) 14 (17.9%) deletion 17p, received BR chemoimmunotherapy. Bendamustine administered at a dose 70 mg/m(2) on days 1 2 375 day 0 the first course 500 during subsequent courses for up six courses.On basis intent-to-treat analysis, overall...
The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical biologic markers were for their impacts on outcome.One hundred nine enrolled, 103 received at least one dose alemtuzumab. After escalation, was administered subcutaneously 30 mg three times weekly up to 12 weeks. Response assessed every 4 weeks during treatment quarterly thereafter.The overall response rate 34% (complete...
Immunoglobulin heavy chain variable-region (VH) gene mutation status and zeta-associated protein 70 (ZAP-70) expression are correlated in chronic lymphocytic leukemia (CLL), but their concordance is variable. The goal of this study was to elucidate additional factors potentially characterizing discordance.We evaluated ZAP-70 by flow cytometry, VH DNA sequencing, genomic aberrations fluorescence situ hybridization 148 CLL patients. parameters were analyzed for associations individual...
Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic leukemia (CLL). Current methods for accurately measuring are problematic, preventing widespread application of these tests clinical decision making. We therefore used comprehensive DNA methylation profiling the regulatory region to identify sites important transcriptional control.High-resolution quantitative analysis entire gene regions was conducted on 247 samples from patients with CLL four independent...
Based on clinical activity in phase 2 studies, lenalidomide was evaluated a 2/3 study patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Following tumor lysis syndrome (TLS) complications, the protocol amended to 1 identify maximum tolerated dose-escalation level (MTDEL). Fifty-two heavily pretreated patients, 69% bulky disease and 48% high-risk genomic abnormalities, initiated at 2.5 mg/day, dose escalation until MTDEL or assigned attained. Lenalidomide safely titrated 20...
BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also lower frequencies hematological malignancies. To assess the potential role of BRAF, we sequenced exons 11 15 138 cases with chronic lymphocytic leukemia (CLL) 32 B-cell prolymphocytic (B-PLL). We found an incidence 2.8% CLL (4/138), while no B-PLL showed mutations. The analysis cohort patients fludarabine-refractory disease (n = 87) increase mutation incidence, suggesting that this is not...